Voyager Therapeutics appoints Catherine J. Mackey, Ph.D. to Board of Directors

Voyager Therapeutics, Inc.

Dr. Mackey appointed as Class I director effective August 15, 2022, serving until 2025 annual meeting.
She joins the Audit Committee and Science and Technology Committee.
Annual cash retainers: $40,000 for Board, $8,000 for Audit, $5,000 for Science & Technology.
Receives initial option for 44,000 shares vesting quarterly over 4 years; annual option for 22,000 shares thereafter.
Dr. Mackey previously was SVP at Pfizer and serves on other biotech boards (IDEAYA, Avid Bioservices, Cour Pharmaceuticals).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine J. Mackey, Ph.D.

director

VYGR · Voyager Therapeutics, Inc.

Effective: 2022-08-15
Filed: July 28, 2022, 7:59 PM ET

On July 27, 2022, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Catherine J. Mackey, Ph.D. as a director of the Company and as a member of both the Audit Committee and the Science and Technology Committee of the Board, effective August 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine J. Mackey, Ph.D. was appointed as director at Voyager Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On July 27, 2022, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Catherine J. Mackey, Ph.D. as a director of the Company and as a member of both the Audit Committee and the Science and Technology Committee of the Board, effective August 15, 2022.

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-083431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.